Compare Amphastar Pharmaceuticals Inc (AMPH) vs Kimberly Clark Corp (KMB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Kimberly Clark Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Kimberly Clark Corp trades at $112.58 (market cap $37.31B). The key difference: Kimberly Clark Corp is far larger — about 45.2× Amphastar Pharmaceuticals Inc's market cap, and Kimberly Clark Corp pays a 4.55% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | KMB | |
|---|---|---|
Market Cap | $826.08M | $37.31B |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $136.77 |
52-Week Low | $16.87 | $93.05 |
Enterprise Value | $1.22B | $43.86B |
Dividend Yield | — | 4.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Kimberly-Clark (KMB) trades at $112.41, up 2.26% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The company maintains strong profitability with a 12.8% net income margin and a high ROE of 146.29%, though revenue declined to $16.45B in 2025. Recent news highlights its dividend reliability and upcoming Q2 2026 results announcement on August 4, 2026.
KMB offers a stable dividend yield and defensive appeal, but faces headwinds from revenue pressure and high valuation multiples. Analyst consensus is mixed with a $109 price target below the current price, suggesting cautious optimism. Key risks include consumer sentiment impacts and input cost inflation, requiring monitoring of margin sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →
